STAT

Opinion: An integrative approach to managing chronic pain can help solve the opioid crisis

Integrative approaches to managing pain offer an effective alternative to opioids and a way to help people break opioid addictions.
Techniques such as acupuncture can be part of an integrative approach to controlling pain as an alternative to opioid use.

President Trump officially made opioid addiction a public health emergency last week. While some of the solutions he outlined will be helpful, his focus on restricting access to legitimately and appropriately prescribed opioids is the wrong approach.

Many people call the current crisis an opioid epidemic. But what we really have is a chronic pain mismanagement problem. I treat patients with chronic pain and opioid addictions. To me, such addictions are the consequence of our failure to provide appropriate treatments for chronic pain. The flood of prescription opioids that has fueled this crisis is in large part the result of prescribing these powerful drugs as a quick solution to mask pain rather than treat its underlying causes.

The National Academy of Medicine estimated that and costs us $600 billion a year. These are more than just numbers that add up to a crisis. These are suffering people and families in need of compassionate, whole-person, and effective approaches to controlling their pain.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy And Ozempic Sales, Rising Pharma Layoffs, And More
Sales of the blockbuster Wegovy obesity treatment more than doubled in the first quarter as Novo Nordisk races to make more of the drug to meet surging demand.
STAT2 min readAmerican Government
STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

Related Books & Audiobooks